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Abstract:	
	
Background	and	Purpose:	Dose	prescription	in	stereotactic	body	radiotherapy	(SBRT)	for	
liver	tumors	is	often	limited	by	the	mean	liver	dose.	We	explore	the	concept	of	
spatiotemporal	fractionation	as	an	approach	to	facilitate	further	dose	escalation	in	liver	
SBRT.		
	
Materials	and	Methods:	Spatiotemporal	fractionation	schemes	aim	at	partial	
hypofractionation	in	the	tumor	along	with	near-uniform	fractionation	in	normal	tissues.	This	
is	achieved	by	delivering	distinct	dose	distributions	in	different	fractions,	which	are	designed	
such	that	each	fraction	delivers	a	high	single	fraction	dose	to	complementary	parts	of	the	
tumor	while	creating	a	similar	dose	bath	in	the	surrounding	noninvolved	liver.	Thereby,	
higher	biologically	effective	doses	(BED)	can	be	delivered	to	the	tumor	without	increasing	
the	mean	BED	in	the	liver.	Planning	of	such	treatments	is	performed	by	simultaneously	
optimizing	multiple	dose	distributions	based	on	their	cumulative	BED.	We	study	this	concept	
for	five	liver	cancer	patients	with	different	tumor	geometries.	
	
Results:	Spatiotemporal	fractionation	presents	a	method	of	increasing	the	ratio	of	
prescribed	tumor	BED	to	mean	BED	in	the	noninvolved	liver	by	approximately	10-20%,	
compared	to	conventional	SBRT	using	identical	fractions.		
	
Conclusions:	Spatiotemporal	fractionation	may	reduce	the	risk	of	liver	toxicity	or	facilitate	
dose	escalation	in	liver	SBRT	in	circumstances	where	the	mean	dose	to	the	non-involved	
liver	is	the	prescription-limiting	factor.		
	
	
Introduction:		
	
Clinical	motivation:	
Liver	stereotactic	body	radiotherapy	(SBRT)	has	become	an	established	treatment	option	for	
primary	and	metastatic	liver	cancer	[1-9].	For	large	tumors,	the	prescription	dose	is	often	
limited	by	the	mean	dose	delivered	to	the	noninvolved	liver.	This	reduces	the	chance	of	
loco-regional	tumor	control	and	warrants	the	exploration	of	novel	concepts	to	allow	for	
further	dose	escalation	[4,	8].		
	
Spatiotemporal	fractionation:	
Fractionated	treatments	face	a	tradeoff.	Increasing	the	number	of	fractions	is	desirable	to	
protect	normal	tissues.	However,	the	total	dose	must	be	increased	to	maintain	tumor	
control	[10].	In	that	sense,	the	ideal	treatment	would	simultaneously	facilitate	
hypofractionation	in	tumors	along	with	near-uniform	fractionation	in	normal	tissues.	
Recently,	it	has	been	shown	that	this	goal	can	be	achieved	to	some	degree	by	delivering	
distinct	dose	distributions	in	different	fractions.	The	concept	has	been	named	
spatiotemporal	fractionation	[11-14].		
	
The	concept	was	initially	demonstrated	for	proton	therapy	[13,	14]	and	subsequently	for	
conventional	photon	beams	[11,	12].	The	rationale	can	be	understood	in	the	context	of	
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rotation	therapy	delivered	with	tomotherapy	or	volumetric-modulated	arc	therapy	(VMAT).	
Distinct	VMAT	plans	for	different	fractions	can	be	designed	in	such	a	way	that	each	fraction	
delivers	a	similar	dose	bath	to	the	normal	tissue	surrounding	the	tumor	(i.e.	exploits	the	
fractionation	effect).	However,	each	fraction	delivers	a	high	single-fraction	dose	to	different	
parts	of	the	target	volume.	Thereby,	some	degree	of	hypofractionation	is	achieved	in	the	
tumor	along	with	near-uniform	fractionation	in	normal	tissues.	Spatiotemporal	fractionation	
was	outlined	as	an	approach	to	improve	fractionated	radiosurgery	for	large	cerebral	
arteriovenous	malformations	[12].	
	
In	this	report,	we	investigate	the	potential	of	spatiotemporal	fractionation	to	improve	the	
ratio	of	tumor	BED	to	mean	liver	BED	in	liver	SBRT.	Thereby,	the	approach	may	reduce	the	
risk	of	radiation-induced	side	effects	in	the	liver.	Alternatively,	spatiotemporal	fractionation	
may	facilitate	dose	escalation	in	liver	SBRT	in	circumstances	where	the	mean	dose	to	the	
non-involved	liver	is	the	prescription-limiting	factor.		
	
	
Methods	
	
Patients:	
We	demonstrate	spatiotemporal	fractionation	for	5	liver	cancer	patients	shown	in	Figure	1.	
These	patients	were	selected	as	to	represent	a	spectrum	of	tumor	geometries,	locations	and	
sizes.	Patient	1	has	4	metastases	of	varying	size	located	throughout	the	right	lobe	of	the	
liver	and	is	discussed	in	detail	in	the	results	section.	The	total	GTV	volume	is	391	cc	and	the	
mean	liver	dose	is	the	dose-limiting	constraint.	Characteristics	of	patients	2-5	are	described	
in	the	supplementary	materials,	Appendix	A.		
	
Modeling	of	fractionation	effects:	
We	consider	SBRT	treatments	with	5	fractions	and	assume	that	the	fractionation	schemes	
summarized	in	Table	1	are	isoeffective.	These	fractionation	effects	can	be	modeled	via	the	
BED	model	[10,	15]	using	generic	values	for	the	!/#-ratio,	i.e.	!/# = 10	in	the	tumor	and	!/# = 4	in	all	normal	tissues.	For	example,	50	Gy	delivered	to	the	tumor	in	5	fractions	is	
equivalent	to	27	Gy	in	a	single	fraction,	and	both	regimens	correspond	to	a	BED10	of	100	Gy.		
	
For	spatiotemporal	fractionation,	we	assume	that	the	BED	model	can	be	extended	to	non-
stationary	fractionation	schemes,	in	which	the	dose	varies	from	fraction	to	fraction.	In	voxel	
i,	the	cumulative	BED	bi	of	all	fractions	is	given	by		() 	= 	 +), + +),.(!/#))1,23 	
where	dit	is	the	dose	delivered	in	fraction	t,	n	is	the	number	of	fractions,	and	(!/#)) 	is	the	!/#-ratio	of	the	structure	that	voxel	i	belongs	to.		
	
For	visualization	and	quantitative	interpretation,	the	BED	can	be	scaled	by	a	factor	1/ 1 + 4/(!/#) ,	where	X	is	a	reference	dose	level	[16].	In	this	report,	we	set	X	to	8	Gy,	i.e.	
to	the	prescribed	dose	per	fraction	in	the	PTV.	This	yields	the	equieffective	dose		
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5678 = (1 + 8(!/#) 	5678	can	be	interpreted	as	the	total	physical	dose	that	needs	to	be	delivered	in	a	
uniformly	fractionated	treatment	with	a	dose	of	8	Gy	per	fraction	to	achieve	the	BED	b.		
	
Treatment	plan	optimization:	
We	simultaneously	optimize	multiple	IMRT	plans	based	on	their	cumulative	BED	
distribution.	Traditional	treatment	plan	optimization	for	IMRT	is	performed	using	objective	
and	constraint	functions	evaluated	for	physical	dose.	Here,	we	apply	the	same	functions	
with	the	difference	that	these	are	evaluated	for	cumulative	BED	rather	than	physical	dose.	
To	derive	BED	constraints	for	normal	tissues	and	BED	prescriptions	for	the	target	volume,	
typical	constraints	and	prescriptions	for	5-fraction	liver	SBRT	were	converted	into	BED1.	We	
consider	the	following	treatment	planning	problem:	
	
Constraints:		 	
	
1. The	maximum	BED4	to	the	bowel,	duodenum	and	stomach	is	constrained	to	75	Gy,	
corresponding	to	30	Gy	physical	dose	in	5	fractions.	
	
Objectives:		
	
1. A	BED10	of	100	Gy	is	prescribed	to	the	GTV	(implemented	via	quadratic	penalty	
functions).	This	corresponds	to	50	Gy	physical	dose	delivered	in	5	fractions.	
2. A	BED10	of	72	Gy	is	prescribed	to	the	PTV,	corresponding	to	40	Gy	physical	dose	in	5	
fractions.	A	BED10	exceeding	100	Gy	is	penalized	quadratically.			
3. A	BED4	to	the	chest	wall	exceeding	120	Gy,	corresponding	to	40	Gy	physical	dose	in	5	
fractions,	is	penalized	quadratically.	
4. The	plan	is	to	be	conformal	(implemented	via	quadratic	penalty	functions	where	the	
allowed	dose	decreases	linearly	with	distance	from	the	PTV).	A	dose	falloff	to	half	
the	PTV	prescription	dose	at	1	cm	distance	from	the	PTV	is	aimed	for.	
5. The	mean	BED4	to	the	healthy	tissue	excluding	the	PTV	and	the	liver	is	minimized.	
6. The	mean	BED4	to	the	liver	excluding	the	GTV	is	minimized.	
	
We	first	optimize	a	treatment	plan	that	delivers	the	same	dose	in	each	fraction,	which	we	
call	the	reference	plan.	This	is	done	based	on	a	weighted	sum	of	the	6	objectives.	Second,	
we	optimize	two	spatiotemporal	plans:	
	
1. Spatiotemporal	plan	1	is	obtained	for	optimizing	the	same	objective	function	as	for	
the	reference	plan,	i.e.	the	same	relative	weighting	of	the	6	objectives.	Hence,	the	
benefit	of	spatiotemporal	fractionation	is	distributed	over	all	objectives.	
																																																						
1	Prescription	doses	and	normal	tissue	constraints	are	based	on	a	Phase	III	trial	to	evaluate	
the	efficacy	of	proton	therapy	against	photon	therapy	conducted	at	Massachusetts	General	
Hospital	(www.clinicaltrials.gov;	Study	title:	Radiation	Therapy	with	Protons	or	Photons	in	
Treating	Patients	with	Liver	Cancer).	These	parameters	also	reflect	institutional	practice	at	
University	Hospital	Zürich.		
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2. Spatiotemporal	plan	2	is	obtained	by	minimizing	the	mean	liver	BED,	subject	to	the	
constraints	that	the	plan	is	no	worse	that	the	reference	plan	for	each	of	the	other	5	
objectives.	Hence,	the	entire	benefit	of	spatiotemporal	fractionation	is	concentrated	
on	reducing	mean	liver	BED.	
	
Details	of	treatment	plan	optimization	are	described	in	the	supplementary	materials,	
Appendix	B.	We	consider	IMRT	plans	consisting	of	19	equispaced	coplanar	beams,	which	
approximates	the	best	coplanar	rotation	therapy	plan,	which	could	be	delivered	with	
tomotherapy	or	VMAT	[17].	We	use	a	beamlet	resolution	of	5x5	mm.		
	
	
Results	
	
Figure	2g	shows	the	dose	distribution	for	patient	1	for	the	reference	plan	that	delivers	the	
same	dose	distribution	in	all	5	fractions.	The	plan	achieves	a	mean	liver	dose	of	18.3	Gy,	
which	is	near	or	exceeding	the	tolerance	for	5-fraction	treatments	[9,	18].	Hence,	the	mean	
liver	dose	represents	the	dose-limiting	constraint.	Figures	2a-e	show	the	spatiotemporal	
treatment	plan	2.	Each	fraction	delivers	a	high	single-fraction	dose	to	complementary	parts	
of	the	tumor.	In	some	places,	single	fraction	doses	exceeding	25	Gy	are	delivered.	Note	that	
a	single-fraction	dose	of	27	Gy	delivers	the	prescribed	BED10	of	100	Gy	to	the	GTV.	However,	
each	fraction	also	delivers	a	similar	dose	bath	to	the	surrounding	healthy	liver	and	thereby	
exploits	the	fractionation	effect.	Figure	2f	illustrates	the	higher	degree	of	fractionation	in	
the	liver	compared	to	the	target.	It	shows,	voxel-by-voxel,	the	percentage	of	the	total	
physical	dose	that	is	delivered	by	the	fraction	that	contributes	the	highest	dose.	A	value	of	
20%	indicates	perfectly	uniform	fractionation.			
	
Figure	2k	shows	the	equieffective	dose	EQD8	for	the	spatiotemporal	treatment	plan,	
demonstrating	that	all	5	fractions	together	deliver	the	prescribed	BED	to	the	target	volume.	
Figure	2l	shows	the	difference	of	EQD8	for	the	reference	plan	(Figure	2j)	and	the	
spatiotemporal	plan	(Figure	2k).	Both	treatments	deliver	approximately	the	same	BED	to	the	
tumor,	but	the	spatiotemporal	plan	yields	lower	mean	BED	in	the	noninvolved	liver	and	the	
unclassified	normal	tissue.	The	mean	liver	BED	is	reduced	by	12.8%	when	considering	the	
liver	without	GTV,	and	by	17.3%	when	considering	the	liver	without	PTV	(Table	2).	This	
benefit	originates	from	the	fact	that	the	spatiotemporal	plan	achieves	the	prescribed	tumor	
BED	with	less	physical	dose.	This	can	be	seen	in	figures	2g-i,	which	show	the	cumulative	
physical	dose	in	the	reference	plan,	the	spatiotemporal	plan,	and	the	difference.	The	mean	
physical	dose	in	the	GTV	is	reduced	by	9.3%.	Figure	3	compares	reference	and	
spatiotemporal	plan	in	terms	of	the	DVH	evaluated	for	EQD8	(a)	and	dose	(b).		
	
Similar	results	have	been	obtained	for	other	patients.	The	spatiotemporal	treatment	plans	
for	patients	2-5	are	shown	in	the	supplementary	materials,	Appendix	C1.	Figure	4a	shows	
the	dose	distributions	of	2	out	of	5	fractions	for	patient	5,	who	harbors	a	large	tumor.	The	
figure	illustrates	that	dose	distributions	that	achieve	a	high	degree	of	fractionation	in	
normal	tissues	along	with	hypofractionation	in	the	tumor	are	not	obvious	and	would	be	
difficult	to	design	manually.	Through	BED-based	planning,	all	dose	distributions	are	created	
automatically	by	the	optimization	algorithm	without	manually	compartmentalizing	the	
target	volume	a	priori.	
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Summary	of	liver	BED	reductions	
Table	2	summarizes	the	results	in	terms	of	mean	liver	BED	reductions.	Spatiotemporal	5-
fraction	treatments	achieve	a	BED	reduction	of	10-20%	in	the	noninvolved	liver.	As	
expected,	the	benefit	is	larger	when	considering	liver	without	GTV	as	opposed	to	liver	
without	PTV,	because	the	degree	to	which	near-uniform	fractionation	is	achieved	is	better	
outside	of	the	PTV	than	inside.	Further	discussion	on	Table	2	is	provided	in	the	
supplementary	materials,	Appendix	C2.		
	
Critical	structures	abutting	the	PTV	
For	liver	SBRT,	the	main	OARs	other	than	the	liver	are	stomach,	bowel,	duodenum,	and	to	a	
lesser	degree	the	chest	wall.	For	patient	4,	the	inferior	part	of	the	tumor	is	surrounded	by	
chest	wall,	bowel	and	stomach.	Assume	the	maximum	BED4	of	75	Gy	is	delivered	to	bowel	
and	stomach.	If	this	is	done	by	delivering	6	Gy	in	each	of	the	5	fractions,	the	overlapping	
part	of	the	PTV	receives	a	BED10	of	48	Gy.	If	instead	15.4	Gy	was	delivered	in	a	single	
fraction	to	reach	the	maximum	BED4	of	75	Gy,	the	BED10	to	the	PTV	would	drop	to	39.1	Gy.	
The	PTV	underdose	is	hence	minimized	for	uniform	fractionation.	In	addition,	the	inferior	
part	of	the	tumor	is	surrounded	by	almost	no	healthy	liver	tissue.	Consequently,	the	benefit	
of	spatiotemporal	fractionation	is	small.	This	is	illustrated	in	figure	4b,	which	shows	that	
spatiotemporal	planning	for	patient	4	results	in	a	near-uniformly	fractionated	plan	that	
avoids	the	high	single-fraction	doses	observed	for	the	other	patient	(see	further	discussion	
in	the	supplementary	materials,	Appendix	C2).	
	
Increasing	the	number	of	fractions	
Above	we	considered	5-fraction	SBRT	treatments	where	each	fraction	delivers	a	distinct	
dose	distribution.	Spatiotemporal	fractionation	can	also	be	applied	to	treatments	with	more	
fractions	while	delivering	each	dose	distributions	multiple	times.	For	example,	a	15-fraction	
treatment	may	consist	of	5	distinct	fractions	that	are	delivered	3	times	each.	This	may	be	
desirable	to	increase	the	fractionation	effect	in	normal	tissues	and	to	mitigate	the	impact	of	
setup	errors.	Generally,	it	is	expected	that	the	benefit	of	spatiotemporal	fractionation	will	
decrease	slightly	if	the	number	of	fractions	is	increased	(while	keeping	the	number	of	
distinct	dose	distributions	equal	to	5).	This	can	be	understood	by	considering	the	
isoeffective	fractionation	schemes	in	Table	1.	For	5-fractions	treatments,	the	physical	dose	
in	the	GTV	can	be	reduced	from	50	Gy	to	27	Gy	in	places	where	the	entire	BED	is	delivered	
in	a	single	fraction.	This	represents	a	46%	reduction	in	physical	dose,	which	can	in	parts	
translate	into	normal	tissue	BED	reduction	depending	on	the	degree	of	fractionation	
achieved	there.	For	15-fraction	treatments	(with	5	distinct	fractions	delivered	3	times	each),	
the	GTV	dose	can	be	reduced	from	68.6	Gy	(in	15	equal	fractions)	to	41.8	Gy	(in	places	
where	the	entire	BED	is	delivered	in	3	fractions).	This	corresponds	to	a	39%	reduction	in	
physical	dose,	i.e.	slightly	lower	than	for	5-fraction	treatments.	For	25-fraction	treatments	
(with	5	distinct	fractions	delivered	5	times	each),	the	physical	dose	can	be	lowered	from	
76.5	Gy	to	50	Gy	(35%).	For	the	liver	without	PTV	for	patient	1,	we	observed	a	11.1%	mean	
liver	BED	reduction	for	15-fraction	treatments	(5x3)	and	a	8.5%	reduction	for	25-fraction	
treatments	(5x5),	which	agrees	with	the	above	considerations	(Table	2).		
	
Alternative	spatiotemporal	fractionation	schemes	
So	far,	we	considered	spatiotemporal	treatments	with	5	distinct	fractions,	leading	to	
treatments	where	each	fraction	delivers	high	single	fraction	doses	to	complementary	parts	
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of	the	target.	Figure	4c	shows	an	alternative	5-fraction	scheme	for	patient	3	with	only	two	
distinct	dose	distributions.	In	this	treatment,	one	plan	is	delivered	4	times	and	the	second	
plan	once.	This	leads	to	a	treatment	scheme	in	which	the	single	fraction	delivers	a	high	dose	
to	the	center	of	the	GTV,	while	the	remaining	4	fractions	primarily	treat	the	PTV	rim	
surrounding	the	GTV.	This	is	an	intuitive	result:	The	single	fraction	hypofractionates	the	GTV	
while	the	remaining	fractions	achieve	a	high	degree	of	fractionation	in	the	normal	liver	
adjacent	to	the	GTV.	However,	the	mean	liver	BED	reduction	compared	to	the	reference	
plan	was	below	5%	and	hence	small	compared	to	treatment	with	5	distinct	fractions	(Table	
2).	
	
	
Discussion	
	
We	demonstrate	that	spatiotemporal	fractionation	can	reduce	the	mean	liver	BED	by	10-
20%	for	a	fixed	prescribed	tumor	BED.	Thus,	the	approach	may	reduce	the	risk	of	radiation-
induced	side	effects	in	the	liver.	Alternatively,	spatiotemporal	fractionation	may	facilitate	
dose	escalation	in	liver	SBRT	in	situations	when	the	prescription	dose	is	limited	by	the	mean	
liver	dose	(rather	than	the	bowel,	stomach	or	duodenum).	Depending	on	the	location	on	the	
dose-response	curve,	this	may	translate	into	substantial	improvements	in	tumor	control	
probability	[4].	Patients	with	large	or	multiple	lesions	that	are	mostly	surrounded	by	
functioning	liver	tissue	are	most	likely	to	benefit	from	spatiotemporal	fractionation.	In	
contrast,	patients	in	whom	the	prescription	dose	is	limited	due	to	the	tumor's	proximity	to	
bowel,	stomach	or	duodenum	are	less	likely	to	benefit	from	spatiotemporal	fractionation.	
	
Stated	vice	versa,	liver	SBRT	is	a	promising	application	for	the	concept	of	spatiotemporal	
fractionation	as	it	fulfils	the	main	requirements.	First,	the	target	volume	mainly	represents	
GTV	that	is	eligible	for	hypofrationation	rather	than	CTV	where	embedded	normal	tissue	
must	be	protected	through	fractionation.	Second,	spatiotemporal	fractionation	can	
primarily	lower	the	mean	dose	to	the	surrounding	normal	tissues.	In	liver	SBRT,	the	mean	
liver	dose	is	often	dose-limiting,	rather	than	the	maximum	dose.	
	
Quantifying	the	fractionation	effect	from	clinical	data	is	generally	problematic	and	!/#-
ratios	are	uncertain.	This	is	in	particular	the	case	for	liver	toxicity	endpoints	because	both	
fractionation	effects	and	dose-volume	effects	need	to	be	accounted	for	in	outcome	
modeling.	Generally,	it	is	expected	that	the	benefit	of	spatiotemporal	fractionation	over	
uniform	fractionation	decreases	with	lower	!/#-ratio	for	the	liver	whereas	a	higher	liver	!/#-ratio	is	in	favor	of	spatiotemporal	fractionation	[14].	However,	the	dependence	of	
mean	liver	BED	reductions	on	the	!/#-ratio	is	weak	within	the	range	of	typically	assumed	
values,	which	was	confirmed	by	treatment	planning	experiments.	For	example,	for	5-
fraction	treatments,	spatiotemporal	plan	2	for	patient	1	yields	an	improvement	in	mean	BED	
in	the	liver	excluding	the	PTV	of	17.3%	(Table	2).	Changing	the	!/#-value	in	the	liver	mean	
BED	objective	to	2,	3,	4,	6,	and	8	(while	all	other	parameters	remain	unchanged)	results	in	
percentage	mean	BED	reductions	of	15.0,	16.3,	17.3,	18.7,	and	19.5.	This	week	dependence	
can	also	be	understood	based	on	the	following	consideration.	In	the	healthy	liver	around	
the	PTV,	where	the	highest	dose	to	normal	tissue	is	expected,	a	uniformly	fractionated	SBRT	
plan	delivers	approximately	a	total	physical	dose	of	40	Gy	in	5	fractions.	Assuming	!/#	=	4,	
this	corresponds	to	a	single-fraction	dose	of	20	Gy.	If	instead	we	assumed	!/#	=	3,	this	
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would	correspond	to	a	single-fraction	dose	of	19.53	Gy.	This	indicates	that	changing	the	!/#-ratio	for	the	normal	tissue	from	4	to	3	corresponds	to	a	small	change	in	what	
fractionation	schemes	are	assumed	to	be	isotoxic.	Hence,	changes	of	the	!/#-ratio	within	
the	range	of	typically	assumed	values	does	not	yield	markedly	different	results	regarding	the	
properties	of	spatiotemporal	treatment	plans.				
	
Respiratory	motion	and	setup	uncertainty	is	a	concern	regarding	spatiotemporal	
fractionation	for	liver	SBRT.	In	this	work,	it	is	assumed	that	the	dose	contributions	of	
different	fractions	are	delivered	as	planned	and	thereby	add	up	to	the	prescribed	BED	in	all	
parts	of	the	target.	Setup	uncertainty	may	lead	to	misalignment	of	dose	contributions	of	
different	fractions,	potentially	causing	target	underdosing.	Future	work	should	devise	
stochastic	programming	methods	to	incorporate	uncertainty	directly	into	treatment	plan	
optimization.	In	conventional	uniformly	fractionated	treatments,	motion	and	setup	
uncertainty	can	be	accounted	for	by	margins.	This	approach	has	limitations	in	
spatiotemporal	fractionation.	Here,	the	target	volume	is	effectively	compartmentalized	into	
distinct	regions	that	are	treated	in	different	fractions.	The	compartmentalization	is	not	
manually	determined	before	treatment	planning.	It	is	optimized	automatically	during	
treatment	plan	optimization.	Hence,	it	is	not	possible	to	manually	design	margins	to	account	
for	inter-fraction	setup	errors.	Therefore,	stochastic	programming	or	robust	optimization	
methods	[19-21]	may	be	a	necessity	to	handle	setup	uncertainty	in	planning.	In	addition,	
technologies	currently	under	development	may	provide	the	tools	to	safely	deliver	
spatiotemporal	liver	SBRT	treatments	in	the	future.	This	includes	the	development	of	MR-
guided	radiotherapy	[22-24]	as	well	as	MLC	and	couch	tracking	[25-32].			
	
	
	Conclusions:	
	
Spatiotemporal	fractionation	may	improve	the	ratio	of	BED	in	the	tumor	to	mean	BED	in	the	
surrounding	liver	by	approximately	10-20%.	This	is	achieved	by	delivering	distinct	dose	
distributions	in	different	fractions	to	facilitate	partial	hypofractionation	in	the	tumor	along	
with	more	uniform	fractionation	in	the	liver.	Therefore,	spatiotemporal	fractionation	may	
lower	side	effects	or	facilitate	dose	escalation	in	liver	SBRT	for	patients	in	whom	the	
prescription	dose	is	limited	by	the	mean	liver	dose.	
	
	
Tables:	
	
	
	
Table	1:	Isoeffective/Isotoxic	fractionation	schemes	corresponding	to	a	tumor	!/#-ratio	of	
10	and	an	!/#-ratio	of	4	in	all	normal	tissues.	
 total dose delivered in n fractions [Gy] BED EQD8 number of fractions n 1 2 3 4 5 15   GTV prescription  27.02 35.83 41.79 46.33 50 68.61 100 55.56 PTV prescription 22.29 29.24 33.84 37.27 40 53.16 72 40 Bowel/Stomach constraint 15.43 20.82 24.59 27.55 30 43.48 75 25 Chest wall constraint 20 27.24 32.42 36.54 40 60 120 40  
Table 1
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Table	2:	Summary	of	liver	BED	reductions	achieved	by	spatiotemporal	fractionation.	By	
definition,	percentage	reductions	in	BED	and	EQD8	are	equal.	The	first	column	indicates	
patient	number,	total	GTV	volume,	and	treatment	scheme	(e.g.	5x3	fx	indicates	a	15-fraction	
treatment	consisting	of	5	distinct	fractions	delivered	3	times	each).	
	
	
   reference spatiotemporal plan 2 spatiotemporal plan 1 Patient Structure mean dose [Gy] dose red.  [%] BED red.  [%] dose red.  [%] BED red.  [%] 1 (391 cc) GTV 51.8 9.3 0 9.5 0 5x1 fx Liver-GTV 18.3 18.2 12.8 14.2 8.4  Liver-PTV 16.2 19.9 17.3 15.0 11.7 2 (201 cc) GTV 51.2 9.2 0 9.2 0 5x1 fx Liver-GTV 11.8 16.1 8.5 11.9 4.5  Liver-PTV 9.0 18.2 15.8 12.5 9.9 3 (207 cc) GTV 51.6 5.8 0 5.8 0 5x1 fx Liver-GTV 18.1 12.0 6.5 9.4 3.8  Liver-PTV 13.0 14.7 12.7 10.7 8.5 4 (228 cc) GTV 52.2 1.4 0 0.6 0 5x1 fx Liver-GTV 9.0 13.7 13.0 2.0 1.4  Liver-PTV 6.5 18.8 20.3 2.5 2.3 5 (647 cc) GTV 51.8 8.4 0 8.2 0 5x1 fx Liver-GTV 18.0 18.9 11.7 12.3 4.5  Liver-PTV 10.5 29.9 28.6 16.3 13.9 1 (391 cc) GTV 71.3 7.0 0 5.9 0 5x3 fx Liver-GTV 23.9 12.9 8.1 9.2 4.7  Liver-PTV 21.0 14.2 11.1 9.9 6.7 1 (391 cc) GTV 79.8 5.4 0 5.0 0 5x5 fx Liver-GTV 26.1 10.4 6.2 7.8 3.8  Liver-PTV 22.8 11.5 8.5 8.4 5.4 3 (391 cc) GTV 51.6 5.5 0 5.4 0 4+1 fx Liver-GTV 18.1 4.0 2.4 2.5 0.7  Liver-PTV 13.0 5.0 4.7 2.7 2.1 
Table 2
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Figure	1:	Patient	geometries.	Contours	show	the	GTV	(red),	PTV	(green),	liver	(beige),	
stomach	(blue),	small	and	large	bowel	(purple),	kidneys	(yellow).	
	
	
(a)	Patient	1,	superior	lesions (b)	Patient	1,	inferior	lesions
(c)	Patient	2 (d)	Patient	3
(e)	Patient	4 (f)	Patient	5
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Figure	2:	Comparison	of	reference	and	spatiotemporal	plan	2	for	the	superior	lesions	of	
patient	1.	(a-e)	Dose	distributions	delivered	in	fractions	1-5;	(f)	portion	of	the	total	dose	
delivered	by	the	hottest	fraction;	(g)	physical	dose	of	the	reference	plan;	(h)	physical	dose	of	
the	spatiotemporal	plan;	(i)	physical	dose	difference;	(j)	EQD8	for	the	reference	plan;	(k)	
EQD8	for	the	spatiotemporal	plan;	(l)	difference	in	EQD8.	In	(i)	and	(l),	the	spatiotemporal	
plan	is	subtracted	for	the	reference	plan;	positive	values	indicate	lower	doses	in	the	
spatiotemporal	plan.		
(a)	fraction	1 (b)	fraction	2 (c)	fraction	3
(d)	fraction	4 (e)	fraction	5 (f)	maximum	relative	dose
(g)	reference	dose (h)	spatiotemporal	dose (i)	dose	difference
(j)	reference	EQD8 (k)	spatiotemporal	EQD8 (l)	EQD8	difference
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Figure	3:	DVH	comparison	of	reference	plan	and	spatiotemporal	plan	2	for	patient	1	for	the	
GTV	and	the	liver	without	PTV.	(a)	EQD8;	(b)	physical	dose.		
	
	
(a)
(b)
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Figure	4:	(a,b)	Two	out	of	5	fractions	for	spatiotemporal	plan	2	for	patient	5	(a)	and	patient	4	
(b)	in	whom	the	tumor	abuts	bowel,	stomach	and	chest	wall;	(c)	spatiotemporal	plan	for	
patient	3	consisting	of	two	distinct	dose	distributions,	in	which	the	left	distribution	is	
delivered	4	times,	the	right	distribution	once.		
	
	
	
(b)	patient	4
(c)	patient	3,	4	+	1	fractions
(a)	patient	5
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Spatiotemporal fractionation schemes for5
6
liver stereotactic body radiotherapy7
8
A Patients9
Five patients were selected as to represent a spectrum of tumor geometries, locations and10
sizes. Patient 1 has 4 metastases of varying size located throughout the right lobe of the liver11
and the total GTV volume is 391 cc. Patient 2 has one lesion (201 cc) peripherally located in12
the right lobe; patient 3 has one large and one small metastasis centrally located in the right13
lobe with a total GTV volume of 207 cc; patient 4 has a single lesion in the inferior part of14
the right lobe (228 cc), which abuts the small bowel, the stomach, and chest wall; patient 515
has one very large lesion (647 cc) in the inferior part of the liver.16
B Treatment plan optimization17
In this section we detail the treatment plan optimization methods. Simultaneous optimiza-18
tion for multiple treatment plans for spatiotemporal fractionstion is based on objective and19
constraint functions evaluated for cumulative BED b.20
1
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B.1 Optimization of reference plan and spatiotemporal plan 121
We solve the following optimization problem:22
minimize f(b) =
1
NG
X
i2G
h
10 (100  bi)2+ + (bi   115.5)2+
i
(GTV, ↵/  = 10) (1)23
+
1
NP
X
i2P
h
10 (72  bi)2+ + (bi   100)2+
i
(PTV, ↵/  = 10) (2)24
+
10
NW
X
i2W
(bi   120)2+ (Chest wall overdose, ↵/  = 4) (3)25
+
1
NR
X
i2R
 
bi   bmaxi
 2
+
(conformity, ↵/  = 4) (4)26
+
1
NH
X
i2H
bi (mean BED remaining healthy tissues, ↵/  = 4) (5)27
+
1
NL
X
i2L
bi (mean BED in the liver without GTV, ↵/  = 4) (6)28
29
subject to bi  75 8i 2 O (maximum BED in OARs, ↵/  = 4) (7)30
bi =
TX
t=1
nt
✓
dti +
(dti)2
(↵/ )i
◆
8i (BED in voxel i in fraction t) (8)31
dti =
X
j
Dijxtj 8i, t (physical dose in voxel i in fraction t) (9)32
xtj   0 8j, t (non-negative fluence) (10)33
Here, t indexes the fractions that deliver distinct dose distributions, T is the number of dis-34
tinct dose distributions, and nt is the number of times fraction t is delivered. Hence, for the35
reference plan we have T = 1. xtj denotes the fluence of beamlet j in fraction t and dti are36
the physical doses per fraction in voxel i in fraction t. The dose-deposition matrix elements37
Dij denotes the dose contributions of beamlets j to voxel i for unit fluence. G and P denote38
the sets of voxels contained in the GTV and the PTV, respectively; W is the set of voxels in39
the chest wall; L denotes all voxels in the liver excluding the GTV; R is the set of voxels in40
a 1 cm margin of normal tissue surrounding the PTV; O denotes the union of voxels in the41
duodenum, small bowel, large bowel, and stomach; and H is the set of all normal tissue voxels42
outside of the PTV that are not in L.43
44
The maximum BED bmaxi in the conformity objective depends linearly on the euclidean45
distance zi of a normal tissue voxel i from the PTV contour:46
bmaxi = 175  zi (175  40) (11)47
Hence, a fallo↵ of the BED from 175 Gy at the edge of the PTV to 40 Gy at 1 cm distance48
is aimed for, corresponding to a physical dose fall-o↵ from 50 Gy to 20 Gy for a uniformly49
2
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fractionated 5-fraction treatment.50
51
To find a local minimum of the optimization problem, we use our own implementation of52
the L-BFGS quasi-Newton method [3], together with an augmented Lagrangian method for53
handling constraints [1]. Calculation of the dose-deposition matrix elements Dij is performed54
with the open-source radiotherapy planning research platform CERR [2]. Fluence maps were55
initialized with small random intensities.56
B.2 Optimization of spatiotemporal plan 257
We denote the objective values for the GTV, PTV, chest wall, conformity, and healthy tissue58
obtained in the reference plan by frefG , f
ref
P , f
ref
W , f
ref
R , and f
ref
H . To obtain the spatiotemporal59
plan 2, we solve the following optimization problem:60
minimize
1
NL
X
i2L
bi (mean liver BED) (12)61
62
subject to frefG  
1
NG
X
i2G
h
10 (100  bi)2+ + (bi   115.5)2+
i
(13)63
frefP  
1
NP
X
i2G
h
10 (72  bi)2+ + (bi   100)2+
i
(14)64
frefW  
10
NW
X
i2W
(bi   120)2+ (15)65
frefR  
1
NR
X
i2R
 
bi   bmaxi
 2
+
(16)66
frefH  
1
NH
X
i2H
bi (17)67
bi  75 8i 2 O (18)68
bi =
TX
t=1
nt
✓
dti +
(dti)2
(↵/ )i
◆
8i (19)69
dti =
X
j
Dijxtj 8i, t (20)70
xtj   0 8j, t (21)71
To obtain the spatiotemporal plan 2, the same optimization algorithm was used. The flu-72
ence maps were initialized using the spatiotemporal plan 1 with small random perturbations.73
Spatiotemporal plans 1 and 2 therefore resulted in qualitatively similar solutions.74
3
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C Results75
C.1 Spatiotemporal treatment plans76
Figure 5 shows the fractional doses delivered in the spatiotemporal treatment plans 2 for all77
patients. The treatment plans for patients 1, 2, 3 and 5 have in common that each fraction78
delivers high single fraction doses to complementary parts of the tumor. This compartmental-79
ization of the target volume is not manually determined. Instead, these dose distributions are80
found automatically through the optimization algorithm. The results for large tumors, such81
as for patient 5, show that the best treatment plans to achieve partial hypofractionation in82
the tumor along with more uniform fractionation in the normal liver are not obvious. Such83
plans would be di cult to design manually. Patient 4 di↵ers from the remaining patients as84
the tumor is surrounded by OARs with maximum BED constraint. Therefore, only a small85
degree of hypofractionation is achieved in the tumor as described in the main manuscript.86
The spatiotemporal plans 1 show the same qualitative features and similar dose distributions87
as the spatiotemporal plans 2.88
C.2 Quantifying the benefit of spatiotemporal fractionation89
In this paper, we report two spatiotemporal treatment plans to quantify the benefit over the90
uniformly fractionated reference plan. Spatiotemporal plan 1 is obtained by minimizing the91
same objective function as for the reference plan. Thereby, the benefit of spatiotemporal92
fractionation is distributed over multiple objectives. The spatiotemporal plan 1 reduces mean93
liver BED but also improves on target coverage and conformity. This has the disadvantage94
that the improvement is di cult to quantify. In spatiotemporal plan 2, the mean liver BED95
is minimized as the only objective, subject to the constraints that the plan is no worse than96
the reference plan in any other objective. Thereby all benefit of spatiotemporal fractionation97
is shifted into reduction of mean liver BED. This has the advantage that the improvement98
of the reference plan can quantified by a single number. However, it can lead to misleading99
observations in certain situations as seen for patients 4 and 5.100
101
For patient 4, a large discrepancy between spatiotemporal plan 1 and 2 regarding their liver102
BED reduction is observed (Table 2). For spatiotemporal plan 1, a small mean liver BED103
of 2% is observed. This is expected because the dose distributions delivered in each of the 5104
fractions is similar. The mean physical dose in the GTV is only 1% lower than in the refer-105
ence plan. This is due to the maximum BED constraint for OARs surrounding the tumor,106
which are best protected through uniform fractionation. For spatiotemporal plan 2, a large107
improvement is observed, which is not explained by the e↵ects of spatiotemporal fractionation108
alone. It is rather due to the location of spatiotemporal plan 1 on the pareto surface that109
characterizes the tradeo↵ between the 6 objectives. For this patient, a small relaxation of110
the first 5 objectives happens to allow for a large improvement in mean liver BED, the 6th111
objective. Hence, the large benefit observed for spatiotemporal plan 2 is technically correct112
but misleading.113
114
A similar e↵ect is observed for patient 5. The large benefit of 29% in spatiotemporal plan 2 is115
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not explained by the e↵ects of spatiotemporal fractionation alone. For this patient the tumor116
involves most of the right lobe. The degree to which the left lobe can be spared depends117
on the conformity of the plan and the dose delivered to the remaining healthy tissue outside118
of the liver. By sacrificing conformity, the dose delivered to the left lobe of the liver can be119
reduced substantially. Spatiotemporal plan 1 yields improvements to all 6 objectives relative120
to the reference plan. Compared to spatiotemporal plan 1, the first 5 objectives are relaxed in121
spatiotemporal plan 2, which allows for an overproportionate improvement in the mean liver122
BED.123
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Figure 5: Dose distributions delivered in 5 fractions for spatiotemporal plan 2. 6
